Bibliographic Details
| Title: |
Tricuspid Regurgitation Disease Stages and Treatment Outcomes After Transcatheter Tricuspid Valve Repair. |
| Authors: |
Schlotter, Florian, Stolz, Lukas, Kresoja, Karl-Patrik, von Stein, Jennifer, Fortmeier, Vera, Koell, Benedikt, Rottbauer, Wolfgang, Kassar, Mohammad, Schöber, Anne, Goebel, Bjoern, Denti, Paolo, Achouh, Paul, Rassaf, Tienush, Rück, Andreas, Zdanyte, Monika, Adamo, Marianna, Vincent, Flavien, Schlegel, Philipp, von Bardeleben, Ralph Stephan, Wild, Mirjam G. |
| Source: |
JACC: Cardiovascular Interventions; Feb2025, Vol. 18 Issue 3, p339-348, 10p |
| Abstract: |
Tricuspid transcatheter edge-to-edge repair (T-TEER) has emerged as a treatment option for patients with severe tricuspid regurgitation (TR). However, randomized trials have not shown a survival benefit, possibly because of the inclusion of patients in an early or too advanced disease stage. The authors sought to investigate the association between disease stage and outcomes following T-TEER. In total, 1,885 patients with significant TR were analyzed, including 585 conservatively treated individuals and 1,300 patients who received T-TEER. Patients were evaluated as part of the prospective EuroTR (European Registry of Transcatheter Repair for Tricuspid Regurgitation) registry and grouped into early, intermediate, and advanced disease stage. Disease stage was based on left and right ventricular function, renal function, and natriuretic peptide levels. The stratification was validated in an external cohort. The primary endpoint was 1-year mortality. Overall, 395 patients (21% [395/1,885]) were categorized as early, 1,173 patients (62% [1,173/1,885]) as intermediate, and 317 patients (17% [317/1,885]) as advanced disease stage. In patients with early and advanced disease, mortality did not differ between interventional and conservative treatment (early-stage HR: 0.78; 95% CI: 0.34-1.80; P = 0.54; advanced stage HR: 1.06; 95% CI: 0.71-1.60; P = 0.78). However, mortality was significantly lower in patients undergoing percutaneous treatment with intermediate disease stage (HR: 0.73; 95% CI: 0.52-0.99; P = 0.03). Compared to medically treated controls, T-TEER was associated with 1-year survival at intermediate stage disease but not at early or advanced disease stages. The timing of T-TEER with regard to disease stages might be crucial to optimize treatment benefits. [Display omitted] [ABSTRACT FROM AUTHOR] |
|
Copyright of JACC: Cardiovascular Interventions is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Supplemental Index |
